It’s 2024. We still don’t know what causes PCOS. We don’t know how to cure it. And we have a limited understanding how to treat it properly. PCOS stands for Polycystic Ovary Syndrome. It’s a syndrome because we don’t really understand it. It’s a syndrome because in medicine ‘syndrome’ refers to a group or collection of symptoms and signs that consistently occur…
Mira, a hormonal health company providing at-home reproductive health solutions, launches an online Hormone Health Clinic for Fertility aimed to help people – struggling to conceive. The clinic provides personalized support from fertility professionals throughout the conception journey, focusing on addressing hormonal imbalances, streamline nutrition and gut health, setting up effective exercise routines and improving mental health. 1 in 5 people in the US are affected by…
May Health, a clinical-stage medical device company dedicated to addressing polycystic ovary syndrome (PCOS), has announced the successful closure of a $25 million Series B financing round. The funding round was co-led by Bpifrance and Trill Impact Ventures, with participation from existing investor Sofinnova Partners, as well as Avestria Ventures and Kidron Capital Assets. PCOS affects approximately 10% of women globally, causing…
San Francisco-based healthcare platform Allara Health has released a study shedding light on the significant productivity loss experienced by individuals with Polycystic Ovary Syndrome (PCOS). Led by Dr. Heather Huddleston, MD, Director of the University of California San Francisco PCOS Clinic, the research aims to understand the professional impact of this chronic hormonal condition on women of reproductive age. Titled “Productivity loss…
This annual initiative is set to raise public awareness and contribute to bridging the gap about female hormonal health. Mira, a hormonal health company providing integrative care and hormonal testing for women, announced the first Sex Hormones Awareness Week in the U.S., set to take place from February 18th to February 24th, 2024. With this initiative, Mira seeks to educate people about their…
Roche Diagnostics has recently received CE-mark regulatory approval for a novel method of diagnosing Polycystic Ovary Syndrome (PCOS), a common endocrine disorder affecting approximately 1 in 8 women of reproductive age. The newly approved Elecsys Anti-Müllerian Hormone (AMH) Plus immunoassay, previously used in fertility diagnostics, now offers a non-invasive alternative to the traditional transvaginal ultrasound for diagnosing PCOS. PCOS, characterized by a…
OOVA, a women’s health platform specializing in remote hormone monitoring, has unveiled its new at-home Perimenopause Hormone Kit. The kit, unique in its approach according to the company, features urine-based multi-hormone biomarkers, including estrogen (E3G), and is complemented by an app that offers real-time data tracking. Differing from traditional blood or FSH-only urine tests, the OOVA kit enables a comprehensive 15-day hormone…
Metabolon, recognized for its contributions in metabolomics, has recently been awarded a grant by the National Institute of Health (NIH). This funding will go towards the development of a more accurate diagnostic test for polycystic ovary syndrome (PCOS). An estimated 8-13% of women are affected by PCOS, yet up to 70% remain undiagnosed. Metabolon’s project, backed by the NIH grant, seeks to…
